Schedule 13G ownership disclosure
Fate Therapeutics Inc
Common Stock, par value $0.001 per share · CUSIP: 31189P102
Event date: 2025-03-31
- Filing-level shares
- 7,794,513.00
- Percent of class
- 6.80%
- Schonfeld Strategic Advisors LLC
Shares: 7,794,513.00 · Class: 6.80%
Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.
Source: SEC EDGAR filingFiling metadata
- Accession number
- 0001193805-25-000667
- Form type
- SCHEDULE 13G
- Filer
- FATE THERAPEUTICS INC
- CIK
- CIK 1434316
- Filed
- May 15, 2025
- Reporting period
- Mar 31, 2025
- Description
- Schedule 13G beneficial ownership